JP7504598B2 - ノズルを構成する中栓及び点眼剤容器 - Google Patents
ノズルを構成する中栓及び点眼剤容器 Download PDFInfo
- Publication number
- JP7504598B2 JP7504598B2 JP2020007831A JP2020007831A JP7504598B2 JP 7504598 B2 JP7504598 B2 JP 7504598B2 JP 2020007831 A JP2020007831 A JP 2020007831A JP 2020007831 A JP2020007831 A JP 2020007831A JP 7504598 B2 JP7504598 B2 JP 7504598B2
- Authority
- JP
- Japan
- Prior art keywords
- mouth
- buffer
- cyclic olefin
- container body
- plug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003889 eye drop Substances 0.000 title claims description 30
- -1 cyclic olefins Chemical class 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 35
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 25
- 239000004713 Cyclic olefin copolymer Substances 0.000 claims description 25
- 229920001577 copolymer Polymers 0.000 claims description 18
- 229920001971 elastomer Polymers 0.000 claims description 16
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 12
- 239000000806 elastomer Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 8
- 229920013716 polyethylene resin Polymers 0.000 claims description 8
- 239000005060 rubber Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 description 26
- 239000011347 resin Substances 0.000 description 26
- 238000001179 sorption measurement Methods 0.000 description 19
- 229940012356 eye drops Drugs 0.000 description 14
- 238000000465 moulding Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 238000007654 immersion Methods 0.000 description 6
- 229920005672 polyolefin resin Polymers 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 4
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229920000092 linear low density polyethylene Polymers 0.000 description 4
- 239000004707 linear low-density polyethylene Substances 0.000 description 4
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004711 α-olefin Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- HANKSFAYJLDDKP-UHFFFAOYSA-N dihydrodicyclopentadiene Chemical compound C12CC=CC2C2CCC1C2 HANKSFAYJLDDKP-UHFFFAOYSA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920006124 polyolefin elastomer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- WLTSXAIICPDFKI-FNORWQNLSA-N (E)-3-dodecene Chemical compound CCCCCCCC\C=C\CC WLTSXAIICPDFKI-FNORWQNLSA-N 0.000 description 1
- GVRWIAHBVAYKIZ-FNORWQNLSA-N (e)-dec-3-ene Chemical compound CCCCCC\C=C\CC GVRWIAHBVAYKIZ-FNORWQNLSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- WLQKHRHCTSEXTL-UHFFFAOYSA-N C1C2CCC1C=C2.C1C2CCC1C=C2 Chemical compound C1C2CCC1C=C2.C1C2CCC1C=C2 WLQKHRHCTSEXTL-UHFFFAOYSA-N 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical group C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical group [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229960001446 distigmine Drugs 0.000 description 1
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical group [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 238000009820 dry lamination Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960002548 epinastine hydrochloride Drugs 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960004834 levobunolol hydrochloride Drugs 0.000 description 1
- 229960001828 levocabastine hydrochloride Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- SUIQUYDRLGGZOL-RCWTXCDDSA-N levofloxacin hemihydrate Chemical compound O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 SUIQUYDRLGGZOL-RCWTXCDDSA-N 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 1
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- 150000002848 norbornenes Chemical class 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical group Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960005071 pirenoxine Drugs 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- BIYQNLJPABKADF-UHFFFAOYSA-M sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 BIYQNLJPABKADF-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 229960004458 tafluprost Drugs 0.000 description 1
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 1
- XBFJAVXCNXDMBH-UHFFFAOYSA-N tetracyclo[6.2.1.1(3,6).0(2,7)]dodec-4-ene Chemical compound C1C(C23)C=CC1C3C1CC2CC1 XBFJAVXCNXDMBH-UHFFFAOYSA-N 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 1
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
- B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D53/00—Sealing or packing elements; Sealings formed by liquid or plastics material
- B65D53/02—Collars or rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Mechanical Engineering (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Closures For Containers (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Description
前記中栓の前記口部に接する外周部は、前記緩衝部を介して前記口部の内面に接する部分よりも前記容器本体の収容部に近い側に、前記接液部が直接前記口部の内面に接触する部分を有してもよい。
前記緩衝部が、ポリエチレン樹脂、ゴム、エラストマーから選択される材料から構成されてもよい。
前記環状オレフィン共重合体(コポリマー)を含む層が、COP(異なる環状オレフィン同士の共重合体)又はCOC(環状オレフィンと非環状オレフィンとの共重合体)の少なくとも1種を含んでもよい。
前記容器本体は、少なくとも内容液に接する面に環状オレフィン共重合体(コポリマー)を含む層を有してもよい。
点眼剤に用いられる有効成分の具体例としては、プロスタグランジン関連薬として、イソプロピルウノプロストン、ラタノプロスト、トラボプロスト、タフルプロスト、ビマトプロスト;非ステロイド性抗炎症薬として、ジクロフェナクナトリウム、プラノプロフェン、ブロムフェナクナトリウム水和物、ネパフェナク;ビタミンB製剤として、シアノコバラミン、フラビンアデニンジヌクレオチドナトリウム;抗アレルギー成分として、アシタザノラスト水和物、アンレキサノクス、イブジラスト、エピナスチン塩酸塩、オロパタジン塩酸塩、クロモグリク酸ナトリウム、ケトチフェンフマル酸塩、トラニラスト、ペミロラストカリウム、レボカバスチン塩酸塩;免疫抑制薬として、シクロスポリン、タクロリムス水和物;β遮断薬として、カルテオロール塩酸塩、チモロールマレイン酸塩、ニプラジロール、ベタキソロール塩酸塩、レボブノロール塩酸塩;α1遮断薬として、ブナゾシン塩酸塩;α2刺激薬として、ブリモニジン酒石酸塩;副交感神経刺激薬として、ピロカルピン塩酸塩;交感神経刺激薬として、ジピベフリン塩酸塩;コリンエステラーゼ阻害薬として、ジスチグミン臭化物;白内障治療薬として、グルタチオン、ピレノキシン;抗菌薬として、ガチフロキサシン水和物、ジベカシン硫酸塩、トスフロキサシントシル酸塩水和物、トブラマイシン、バンコマイシン塩酸塩、モキシフロキサシン塩酸塩、レボフロキサシン水和物、塩酸ロメフロキサシン、オフロキサシン、クロラムフェニコール、ノルフロキサシン;β遮断薬・炭酸脱水酵素阻害薬配合剤として、ドルゾラミド塩酸塩、ブリンゾラミド等が挙げられる。
本実施形態の中栓を有する滴下容器は、点眼剤容器に限らず、他の内容物を収容する容器に適用することも可能である。例えば点鼻剤、点耳剤、その他、投与に際して薬液を患部に滴下する方式の薬剤または化粧水などの容器が挙げられる。
環状オレフィン共重合体(コポリマー)を含む層において、環状オレフィン共重合体(コポリマー)に代えて、又は環状オレフィン共重合体(コポリマー)と共に、環状オレフィンの単独重合体、又はその水素添加物を配合することも可能である。
中栓本体部の材質をCOP、緩衝部の材質をPEとし、外周面に環状の緩衝部を有する中栓を作製した。実施例1では、中栓本体部の脚部の内側に空隙部を介して内筒部を設けた。実施例2では、中栓本体部の脚部の内側がノズル孔まで樹脂で充填された構造とした。比較のため、比較例1では、緩衝部を省略して、PEで中栓を作製した。
直径24mm、高さ45mmの褐色ガラス瓶に中栓をそれぞれ1個と、内容液として株式会社資生堂の化粧水「リバイタル(登録商標)ローションEX I」を3ml入れ、アルミテープで封をした。中栓全体を内容液に浸漬させ、蓋にアルミテープを用いて褐色ガラス瓶の口を密封して、温度40℃、相対湿度75%の環境下で保管した。中栓を浸漬する前の内容液における酢酸トコフェロール(ビタミンE)の濃度(初期濃度)は、約477ppmであった。28日間保管した後の内容液における酢酸トコフェロール(ビタミンE)の濃度(浸漬後濃度)を測定した。初期濃度と浸漬後濃度とから、残存率を次の式1のように算出した。
(式1) 残存率(%)=(浸漬後濃度/初期濃度)×100(%)
実施例2では、浸漬後濃度は約428ppm、残存率は約89.7%であった。
比較例1では、浸漬後濃度は約341ppm、残存率は約71.5%であった。
収容部の容量が6.9mlで、最内層が環状オレフィン樹脂からなる容器本体を準備した。この容器本体の口部に、それぞれ実施例1、2又は比較例1、2の中栓を装着した。なお、実施例1、2及び比較例1の中栓は、残存率の測定で用いたものと同じである。また、比較例2の中栓は、環状オレフィン樹脂で全体を作製した。
実施例1、2では、容器本体の口部において、中栓の緩衝部が環状オレフィン樹脂の最内層に接触するように構成されている。
比較例2では、容器本体の口部と中栓との接触部に漏れが確認された。
容器本体の口部に接する外周部に緩衝部を設けた実施例1、2では、成分の残存率が高く、口部と中栓との接触部に漏れがなかった。
中栓全体をPEから構成した比較例1では、口部と中栓との接触部に漏れはなかったが、成分の残存率が低くなった。
中栓全体を環状オレフィン樹脂から構成した比較例2では、成分の残存率は実施例1、2と同様に高いと推測されるが、口部と中栓との接触部に中身の漏れが生じた。
以上の結果から、実施例1、2の中栓によれば、中栓への点眼剤の収着(吸着、吸収)を抑制しつつ、中栓と容器本体との間に隙間や漏れが生じにくいことが確認された。
Claims (6)
- 容器本体の口部に装着されてノズルを構成する中栓であって、
環状オレフィン共重合体(コポリマー)を含む層からなる接液部と、前記口部に接する外周部に設けられた緩衝部とを有し、前記緩衝部は、ポリエチレン樹脂、ゴム、エラストマーから選択される材料から構成されることを特徴とする中栓。 - 前記中栓は、前記口部の先端面に接触するフランジ部と、前記口部の内面に接触する脚部とを有し、前記緩衝部は、少なくとも前記脚部の外周面に設けられていることを特徴とする請求項1に記載の中栓。
- 前記中栓の前記口部に接する外周部は、前記緩衝部を介して前記口部の内面に接する部分よりも前記容器本体の収容部に近い側に、前記接液部が直接前記口部の内面に接触する部分を有することを特徴とする請求項1又は2に記載の中栓。
- 前記環状オレフィン共重合体(コポリマー)を含む層が、COP(異なる環状オレフィン同士の共重合体)又はCOC(環状オレフィンと非環状オレフィンとの共重合体)の少なくとも1種を含むことを特徴とする請求項1~3のいずれか1項に記載の中栓。
- 請求項1~4のいずれか1項に記載の中栓と、前記中栓が装着される口部を有する容器本体とを備えることを特徴とする点眼剤容器。
- 前記容器本体は、少なくとも内容液に接する面に環状オレフィン共重合体(コポリマー)を含む層を有することを特徴とする請求項5に記載の点眼剤容器。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020007831A JP7504598B2 (ja) | 2020-01-21 | 2020-01-21 | ノズルを構成する中栓及び点眼剤容器 |
CN202180010049.3A CN115023397A (zh) | 2020-01-21 | 2021-01-20 | 构成喷嘴的内塞及滴眼剂容器 |
US17/793,731 US20230088243A1 (en) | 2020-01-21 | 2021-01-20 | Inner Plug Constituting Nozzle And Eye Drop Container |
PCT/JP2021/001816 WO2021149712A1 (ja) | 2020-01-21 | 2021-01-20 | ノズルを構成する中栓及び点眼剤容器 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020007831A JP7504598B2 (ja) | 2020-01-21 | 2020-01-21 | ノズルを構成する中栓及び点眼剤容器 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024092988A Division JP2024103798A (ja) | 2024-06-07 | ノズルを構成する中栓及び点眼剤容器 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021113088A JP2021113088A (ja) | 2021-08-05 |
JP7504598B2 true JP7504598B2 (ja) | 2024-06-24 |
Family
ID=76992943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020007831A Active JP7504598B2 (ja) | 2020-01-21 | 2020-01-21 | ノズルを構成する中栓及び点眼剤容器 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230088243A1 (ja) |
JP (1) | JP7504598B2 (ja) |
CN (1) | CN115023397A (ja) |
WO (1) | WO2021149712A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230064423A1 (en) * | 2020-02-13 | 2023-03-02 | West Pharmaceutical Services, Inc. | Containment and delivery systems for cryogenic storage |
JP7477319B2 (ja) * | 2020-02-28 | 2024-05-01 | 藤森工業株式会社 | ノズルを構成する中栓及び点眼剤容器 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015016871A (ja) | 2013-07-09 | 2015-01-29 | 伸晃化学株式会社 | 製剤容器 |
JP2015535782A (ja) | 2012-09-25 | 2015-12-17 | アプタル ラドルフツエル ゲーエムベーハ | 液体分配器 |
JP2017145039A (ja) | 2016-02-19 | 2017-08-24 | 大成化工株式会社 | 液体容器 |
JP2017197524A (ja) | 2016-04-22 | 2017-11-02 | ロート製薬株式会社 | 眼科組成物 |
WO2018190422A1 (ja) | 2017-04-13 | 2018-10-18 | ロート製薬株式会社 | スクイズボトル |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1147384A (en) * | 1915-01-21 | 1915-07-20 | Robert C Fetzer Jr | Bottle-closure. |
US1436708A (en) * | 1922-04-03 | 1922-11-28 | John H Goebel | Pouring nozzle for bottles |
US2727659A (en) * | 1950-09-08 | 1955-12-20 | Continental Can Co | Container arranged with a spout in one end |
US3422998A (en) * | 1968-03-11 | 1969-01-21 | Leonard J Murray | Pour spout adapter |
JPS4829316Y1 (ja) * | 1970-12-22 | 1973-09-05 | ||
US7527180B2 (en) * | 2004-04-02 | 2009-05-05 | Howard Silvers & Sons Pty Limited | Drink pouring dispenser |
WO2007102566A1 (ja) * | 2006-03-06 | 2007-09-13 | Toyo Seikan Kaisha, Ltd. | 複合スパウト及び複合スパウトを形成する射出成形装置 |
FR2915971B1 (fr) * | 2007-05-11 | 2012-01-20 | Periscope Internat | Dispositif de type bouchon doseur, pour la distribution d'un volume determine d'un liquide conditionne en bouteille. |
ES2457528T3 (es) * | 2007-07-20 | 2014-04-28 | Otsuka Pharmaceutical Factory, Inc. | Recipiente de medicina y película multicapa |
US20120271252A1 (en) * | 2009-09-24 | 2012-10-25 | Senju Pharmaceutical Co., Ltd. | Medical fluid nozzle |
US20110297703A1 (en) * | 2010-06-07 | 2011-12-08 | Mccormick & Company, Incorporated | Mess free dispensing nozzle and container with suck back feature |
WO2014203770A1 (ja) * | 2013-06-21 | 2014-12-24 | 三菱瓦斯化学株式会社 | 吸収剤含有容器 |
JP6242216B2 (ja) * | 2013-10-03 | 2017-12-06 | 住友化学株式会社 | 中栓、吸い上げ式液体容器 |
JP6665084B2 (ja) * | 2014-04-18 | 2020-03-13 | 東洋製罐株式会社 | 粘稠内容物の充填方法 |
ES2742226T3 (es) * | 2014-12-19 | 2020-02-13 | Kyoraku Co Ltd | Recipiente deslaminable y procedimiento para fijar una tapa al mismo |
WO2016139943A1 (ja) * | 2015-03-02 | 2016-09-09 | 東洋製罐グループホールディングス株式会社 | ノズル |
US11046489B2 (en) * | 2015-12-25 | 2021-06-29 | Iwasaki Industry Inc. | Food container and method for manufacturing same |
-
2020
- 2020-01-21 JP JP2020007831A patent/JP7504598B2/ja active Active
-
2021
- 2021-01-20 US US17/793,731 patent/US20230088243A1/en active Pending
- 2021-01-20 CN CN202180010049.3A patent/CN115023397A/zh active Pending
- 2021-01-20 WO PCT/JP2021/001816 patent/WO2021149712A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015535782A (ja) | 2012-09-25 | 2015-12-17 | アプタル ラドルフツエル ゲーエムベーハ | 液体分配器 |
JP2015016871A (ja) | 2013-07-09 | 2015-01-29 | 伸晃化学株式会社 | 製剤容器 |
JP2017145039A (ja) | 2016-02-19 | 2017-08-24 | 大成化工株式会社 | 液体容器 |
JP2017197524A (ja) | 2016-04-22 | 2017-11-02 | ロート製薬株式会社 | 眼科組成物 |
WO2018190422A1 (ja) | 2017-04-13 | 2018-10-18 | ロート製薬株式会社 | スクイズボトル |
Also Published As
Publication number | Publication date |
---|---|
WO2021149712A1 (ja) | 2021-07-29 |
CN115023397A (zh) | 2022-09-06 |
US20230088243A1 (en) | 2023-03-23 |
JP2021113088A (ja) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7504598B2 (ja) | ノズルを構成する中栓及び点眼剤容器 | |
KR100999705B1 (ko) | 약액 충전 플라스틱 앰플 및 그의 제조 방법 | |
EP2330048B1 (en) | Multilayered liquid container | |
KR100953352B1 (ko) | 산소흡수성 수지 조성물 및 이것을 사용한 산소흡수성 용기캡 및 산소흡수성 용기마개부 | |
KR102567417B1 (ko) | 튜브 용기 | |
EP2311430A1 (en) | A plastic container comprising cyclic polyolefin layer | |
JP2007284066A (ja) | 水中油型又は油中水型乳化物を収容した製品及び多層構造容器 | |
JP2023052479A (ja) | 積層体およびプラスチック容器 | |
JP2024103798A (ja) | ノズルを構成する中栓及び点眼剤容器 | |
JP7477319B2 (ja) | ノズルを構成する中栓及び点眼剤容器 | |
KR102665924B1 (ko) | 플라스틱 용기 | |
US20220055357A1 (en) | Ophthalmic solution container | |
JP2021178646A (ja) | 点眼剤容器 | |
JP2021178645A (ja) | 点眼剤容器 | |
JP2021177839A (ja) | 点眼剤容器 | |
JP7398267B2 (ja) | 点眼剤容器 | |
JP3803585B2 (ja) | 2重エアゾール容器及び2連缶容器 | |
US20240122806A1 (en) | Container multilayered body, container, medical container, and drug-containing medical container | |
JP4320809B2 (ja) | 耐薬品性に優れた多層プラスチックチューブ容器 | |
JP2019077129A (ja) | 積層フィルム及び包装袋 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240612 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7504598 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |